Siegall is a distinguished doctor with several years of experience in the pharmaceutical industry. His professional credentials and knowledge will serve the interests of Mirna Pharmaceuticals well, according to company CEO Paul Lammers.
MicroRNA therapeutics is the core of cancer research. “The possibilities are endless,” according to Siegall. “Mirna has positioned itself well with a strong stream of exciting candidates.” Siegall went on to say that the research is promising and the advancements will do wonders for patients who are badly in need of new medicines.
Mirna Therapeutics has been working on a number of medicines for years. They also conduct clinical trials throughout the U.S. to learn more about the effectiveness of medicines. “We are very close to making breakthroughs,” said Siegall. “It’s only a matter of time that we will have vastly improved medicines to help all cancer sufferers.”
Dr. Siegall Clay B. Siegall founded Seattle Genetics in 1998. A trained scientist, it was Siegall’s goal to develop targeted research therapies for helping cancer patients. In 2011, Seattle Genetics received a patent in collaboration with Japanese pharmaceutical company Takeda for the cancer-treatment drug ADCERTIS. The FDA approved drug is available in over 60 countries.
Through Siegall’s leadership, Seattle Genetics has created partnerships with several pharmaceutical companies for the purpose of research. He has also secured over $1 billion in private funding.
Prior to Seattle Genetics, he worked for the National Institute of Health and Bristol Meyers Squibb. Dr. Clay Siegall has also been published dozens of times and holds 7 patents. He received a bachelors degree in Zoology from the University of Maryland and his genetics PhD from George Washington University.